<DOC>
	<DOC>NCT02439775</DOC>
	<brief_summary>The purpose of this study is to obtain an assessment of the efficacy and safety of renal denervation in the presence of three standard antihypertensive medications.</brief_summary>
	<brief_title>SPYRAL HTN-ON MED Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<criteria>Individual has office systolic blood pressure (SBP) ≥ 150 mmHg and &lt;180 mmHg and a diastolic blood pressure (DBP) ≥ 90 mmHg after being off medications. Individual has 24hour Ambulatory Blood Pressure Monitoring (ABPM) average SBP ≥ 140 mmHg and &lt; 170 mmHg. Individual lacks appropriate renal artery anatomy. Individual has estimated glomerular filtration rate (eGFR) of &lt;45. Individual has type 1 diabetes mellitus or poorlycontrolled type 2 diabetes mellitus. Individual has one or more episodes of orthostatic hypotension. Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea. Individual has primary pulmonary hypertension. Individual is pregnant, nursing or planning to become pregnant. Individual is being treated chronically (e.g. daily use) with nonsteroidal antiinflammatory drugs (NSAIDs). Aspirin therapy is allowed. Individual has experienced a myocardial infarction, unstable angina pectoris, syncope, or a cerebrovascular accident within three months of the screening period, or has widespread atherosclerosis, with documented intravascular thrombosis or unstable plaques. Individual works night shifts.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Uncontrolled hypertension</keyword>
	<keyword>Renal denervation</keyword>
</DOC>